000131827 001__ 131827
000131827 005__ 20240219150722.0
000131827 0247_ $$2doi$$a10.1016/j.msard.2021.102995
000131827 0248_ $$2sideral$$a137007
000131827 037__ $$aART-2021-137007
000131827 041__ $$aeng
000131827 100__ $$0(orcid)0000-0002-1756-5492$$aGarcés Redondo, Moisés$$uUniversidad de Zaragoza
000131827 245__ $$aResponse to hepatitis B vaccine in patients with multiple sclerosis: preliminary data
000131827 260__ $$c2021
000131827 5203_ $$aBackground
Studies in different autoimmune pathologies report a lower response rate (immunogenicity) to vaccinations than in the general population. Our objective is to analyze the immunogenicity of the vaccine against hepatitis B virus (HBV) in patients with multiple sclerosis (MS).
Methods
In a single prospective cohort of MS patients with negative HBV serology, hepatitis B (rDNA) B vaccine was administered at 0, 1 and 6 months. Immunogenicity was analyzed by the determination of antibodies to surface antigens of HBV. We considered a patient as a responder if antibodies level was higher than 10 IU/L. Posterior analysis of immunogenicity was conducted by demographic variables (e.g. MS phenotype, EDSS) and use of disease-modifying drugs (DMTs).
Results
Vaccination study of 251 patients: 160 of them were sero-negative (63.7%). Patients vaccinated: 99. Overall response: 74.1%. No significant relationship by sex (female 77.6% responders, male 68.8%) and MS phenotype (relapsing forms 74.3% responders, secondary progressive 50%). Variables associated with significantly lower immunogenicity were: age (>55 years), EDSS score (median: non-responders=3.0, responders=1.0), number of relapses and treatment with fingolimod (28.6% responders, n=7). Anti-CD20 therapies showed lower vaccine response (50%), but were not very represented in our sample (n=2). Immunogenicity with other DMTs: interferon/glatiramer 69.6% (n=23), teriflunomide 71.4% (n=14), dimethylfumarate 92.3% (n=13), natalizumab 100% (n=7).
Conclusion
The overall immunogenicity of our sample is lower than that reported in the general population (74 vs >86%), as in other autoimmune diseases. Preliminary data show a lower immunogenicity with older age, higher EDSS score, number of relapses and fingolimod use.
000131827 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000131827 590__ $$a4.808$$b2021
000131827 591__ $$aCLINICAL NEUROLOGY$$b64 / 212 = 0.302$$c2021$$dQ2$$eT1
000131827 592__ $$a1.006$$b2021
000131827 593__ $$aNeurology$$c2021$$dQ1
000131827 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000131827 594__ $$a5.0$$b2021
000131827 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion
000131827 700__ $$aVal Lafaja, Alodia de$$uUniversidad de Zaragoza
000131827 700__ $$0(orcid)0000-0003-0715-2843$$aAtienza Ayala, Saida$$uUniversidad de Zaragoza
000131827 700__ $$aGarcés Antón, Esther$$uUniversidad de Zaragoza
000131827 700__ $$0(orcid)0000-0001-6839-7751$$aMarín Gracia, Carmen Marta
000131827 700__ $$0(orcid)0000-0002-9233-1960$$aRomán Calderón, Francisco
000131827 700__ $$0(orcid)0000-0002-4528-1921$$aLópez Mendoza, Héctor
000131827 700__ $$aChaure Pardos, Armando
000131827 700__ $$0(orcid)0000-0003-2313-2762$$aHernández García, Ignacio
000131827 700__ $$0(orcid)0000-0002-2711-066X$$aÍñiguez Martínez, Cristina$$uUniversidad de Zaragoza
000131827 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000131827 773__ $$g51 (2021), 102995 [2 pp.]$$pMult. scler. relat. disord.$$tMultiple Sclerosis and Related Disorders$$x2211-0348
000131827 8564_ $$s126012$$uhttps://zaguan.unizar.es/record/131827/files/texto_completo.pdf$$yVersión publicada
000131827 8564_ $$s3394767$$uhttps://zaguan.unizar.es/record/131827/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131827 909CO $$ooai:zaguan.unizar.es:131827$$particulos$$pdriver
000131827 951__ $$a2024-02-19-13:27:51
000131827 980__ $$aARTICLE